411 related articles for article (PubMed ID: 33483918)
21. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study.
Hetland ML; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Svendsen A; Pedersen JK; Skjødt H; Lauridsen UB; Ellingsen T; Hansen GV; Lindegaard H; Vestergaard A; Jurik AG; Østergaard M; Hørslev-Petersen K;
Ann Rheum Dis; 2008 Jun; 67(6):815-22. PubMed ID: 17878209
[TBL] [Abstract][Full Text] [Related]
22. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
Aletaha D; Smolen JS
Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
[TBL] [Abstract][Full Text] [Related]
23. [Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice].
La Montagna G; Tirri R; Vitello R; Malesci D; Buono R; Mennillo G; Valentini G
Reumatismo; 2006; 58(4):261-7. PubMed ID: 17216014
[TBL] [Abstract][Full Text] [Related]
24. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
26. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
[TBL] [Abstract][Full Text] [Related]
27. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.
Moura CS; Abrahamowicz M; Beauchamp ME; Lacaille D; Wang Y; Boire G; Fortin PR; Bessette L; Bombardier C; Widdifield J; Hanly JG; Feldman D; Maksymowych W; Peschken C; Barnabe C; Edworthy S; Bernatsky S;
Arthritis Res Ther; 2015 Aug; 17(1):197. PubMed ID: 26235697
[TBL] [Abstract][Full Text] [Related]
28. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
[TBL] [Abstract][Full Text] [Related]
29. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
30. Comparison of intra-articular glucocorticoid injections with DMARDs versus DMARDs alone in rheumatoid arthritis.
Menon N; Kothari SY; Gogna A; Sharma R
J Assoc Physicians India; 2014 Aug; 62(8):673-6. PubMed ID: 25856933
[TBL] [Abstract][Full Text] [Related]
31. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.
Takamura A; Hirata S; Nagasawa H; Kameda H; Seto Y; Atsumi T; Dohi M; Koike T; Miyasaka N; Harigai M
Mod Rheumatol; 2013 Mar; 23(2):297-303. PubMed ID: 22572888
[TBL] [Abstract][Full Text] [Related]
32. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
Koyama Y; Shiraishi H; Ohta T; Uchino A
Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
[TBL] [Abstract][Full Text] [Related]
33. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
Osiri M; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
[TBL] [Abstract][Full Text] [Related]
34. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
[TBL] [Abstract][Full Text] [Related]
35. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
[TBL] [Abstract][Full Text] [Related]
36. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.
Shi ZC; Fei HP; Wang ZL
Medicine (Baltimore); 2020 Jan; 99(3):e16635. PubMed ID: 32011430
[TBL] [Abstract][Full Text] [Related]
38. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
[TBL] [Abstract][Full Text] [Related]
39. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
Kristensen LE; Saxne T; Nilsson JA; Geborek P
Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.
Huang Y; Chatterjee S; Agarwal SK; Chen H; Johnson ML; Aparasu RR
Explor Res Clin Soc Pharm; 2023 Sep; 11():100296. PubMed ID: 37521021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
